Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

Capsida Biotherapeutics yesterday revealed US pharma major AbbVie has exercised an option for the first neurodegenerative ...

Capsida Biotherapeutics ("Capsida") today announced that AbbVie has exercised an option for the first neurodegenerative ...

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.

In addition to its wholly owned programs, the Company has validating partnerships with AbbVie, Lilly, and CRISPR Therapeutics. Capsida was founded in 2019 by lead investors Versant Ventures and ...

Jan 6 (Reuters) - AbbVie (ABBV.N), opens new tab lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as ...

Pharmaceutical giant AbbVie Inc. has agreed to acquire Madison's Nimble Therapeutics Inc. for $200 million in cash. Pharmaceutical giant AbbVie Inc. has agreed to acquire Madison's Nimble ...